| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $51.8M | — | +6.4% |
| SG&A Expense | $50.2M | — | +76.7% |
| Operating Income | -$102.0M | — | -32.3% |
| Net Income | -$105.5M | — | -41.2% |
| EPS (Basic) | -$0.83 | — | -23.9% |
| EPS (Diluted) | -$0.83 | — | -23.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $430.5M | +33.1% | +212.2% |
| Short-term Investments | $49.4M | +12.2% | -78.2% |
| Current Assets | $515.3M | +33.8% | +33.8% |
| Total Assets | $535.3M | +32.4% | +31.3% |
| Current Liabilities | $59.6M | +7.6% | +58.7% |
| Long-term Debt | $196.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$82.1M | — | -4.4% |
| Capital Expenditures | $68K | — | -74.9% |
| Investing Cash Flow | -$5.3M | — | -115.4% |
| Financing Cash Flow | $193.8M | — | +4548.3% |
| Free Cash Flow | -$82.2M | — | -4.1% |
| +295.3% |
| Total Liabilities | $259.2M | +63.3% | +172.3% |
| Stockholders' Equity | $276.0M | +12.4% | -11.6% |